Dataset Information


Whole abdominopelvic intensity-modulated radiation therapy for desmoplastic small round cell tumor after surgery.

ABSTRACT: Desmoplastic small round cell tumor (DSCRT) is an uncommon pediatric tumor with a poor prognosis. Aggressive multimodality therapy is the current treatment approach; however. treatment toxicity is of concern. We report our results with whole abdominopelvic intensity-modulated radiation therapy (WAP-IMRT) as a component of multimodality therapy for DSCRT at a single institution.Medical records of all patients with DSCRT who received WAP-IMRT as part of definitive treatment at MD Anderson (2006-2010) were identified and reviewed.Eight patients with DSRCT received WAP-IMRT with a median follow-up of 15.2 months. All patients received multiple courses of chemotherapy followed by surgical debulking of intra-abdominal disease; seven also had intraoperative hyperthermic cisplatin. WAP-IMRT was delivered to a total dose of 30 Gy postoperatively; four patients received a simultaneous boost (6-10 Gy) to sites of gross residual disease. Seven patients received concurrent chemotherapy during WAP-IMRT. No Radiation Therapy Oncology Group Grade 4 nausea, vomiting, or diarrhea occurred during RT. Red-cell transfusions were given to two patients to maintain hemoglobin levels >10 g/dL. Grade 4 cytopenia requiring growth factor support occurred in only one patient; no other significant cytopenias were noted. WAP-IMRT resulted in 25% lower radiation doses to the lumbosacral vertebral bodies and pelvic bones than conventional RT plans. The median time to local or distant failure after WAP-IMRT was 8.73 months in seven patients. One patient who had completed RT 20 months before the last follow-up remains alive without evidence of disease. Five patients (63%) experienced treatment failure in the abdomen. Distant failure occurred in three patients (37.5%).WAP-IMRT with concurrent radiosensitizing chemotherapy was well tolerated after aggressive surgery for DSCRT. Enhanced bone sparing with IMRT probably accounts for the low hematologic toxicity (vs. conventional WAP-RT). This modality should be considered as an additional local-regional control option for DSRCT.


PROVIDER: S-EPMC4005898 | BioStudies | 2012-01-01

REPOSITORIES: biostudies

Similar Datasets

2017-01-01 | S-EPMC5325210 | BioStudies
2019-01-01 | S-EPMC6805982 | BioStudies
1000-01-01 | S-EPMC6156886 | BioStudies
2018-01-01 | S-EPMC6097832 | BioStudies
2018-01-01 | S-EPMC6123184 | BioStudies
1000-01-01 | S-EPMC3987089 | BioStudies
2020-01-01 | S-EPMC7276694 | BioStudies
2015-01-01 | S-EPMC4915591 | BioStudies
1000-01-01 | S-EPMC3599957 | BioStudies
2017-01-01 | S-EPMC5721605 | BioStudies